







With BD SurePath<sup>™</sup>, you don't need to worry about discarding cells that could mean the difference between finding dysplasia and missing it! (1).

#### **References:**

(1) Bigras, G et al. J of Lower Genital Tract Disease. Vol 7 (3), 2003: 168-174. (2) Sweeney BJ, et al. Cancer Cytopathology. Vol 108 (1), 2006: 27-31.

Product availability has to be confirmed by your local representative.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company, © 2010 BD, XEUR5114-09. Becton Dickinson GmbH Tullastrasse 8-12, D-69126 Heidelberg. Sitz: Heidelberg. Geschäftsführer: Matthias Borst Amtsgericht Mannheim HRB 330 707.



Added Blood (uL)

**BD** Diagnostics Women's Health and Cancer Tullastrasse 8-12 D-69126 Heidelberg Germany

For Europe, Middle East and Africa Phone: +32 53 720 211 Email: TriPathEurope@BD.com www.bd.com

<ul> <li>Liquid-based cytology</li> <li>Liquid-based cytology</li> <li>Liquid-based cytology</li> <li>Computer-guided screening</li> <li>Immuno-chemistry</li> <li>Immuno-chemistry</li> </ul>	
	Helping all people live healthy lives
	Find what you are looking for
	Rely on the FDA-approved
	<b>BD FocalPoint<sup>™</sup> GS Imaging System</b> for efficient and optimal interpretation of your slides



### **References:**

(1) Package insert of BD FocalPoint<sup>™</sup> GS Imaging System.
(2) Wilbur DC., Parker EM., Foti JA. Location-Guided Screening of Liquid-Based Cervical Cytology Specimens. A Potential Improvement in Accuracy and Productivity is Demonstrated in a Preclinical Feasibility Trial. Am J Clin Path 2002;118:399-407.
(3) Passamonti B., Bulletti S., Camilli M., D'Amico M., Di Dato E., Gustinuchi D., Martinelli N., Malaspina M., Spitta N. Evaluation of the FocalPoint GS System Performance in an Italian Population-Based Screening of Cervical Abnormalities. Acta Cytologica 2007;51(6):865-871.
(4) Huang TW., Lin TS., Lee JS. Sensitivity studies of the AutoPap System Location Guided Screening of cervical-vaginal cytologic smears. Acta Cytologica 1999;43:363-368.
(5) Bentz JS. Liquid-based cytology for cervical cancer screening. Future Drugs 2005; 5(6), 857-871.
(6) Lee JS., Kuan L., Oh S., Patten F., Wilbur DC. A feasibility study of the AutoPap System Location Guided Screening. Acta Cytologica 1998;42:221-226.

(7) Kardos T. The FocalPoint System: FocalPoint slide profiler and FocalPoint GS. Cancer Cytopathology. Dec 2004.

Product availability has to be confirmed by your local representative.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2010 BD. XEUR5115-09. Becton Dickinson GmbH Tullastrasse 8-12, D-69126 Heidelberg. Sitz: Heidelberg. Geschäftsführer: Matthias Borst. Amtsgericht Mannheim HRB 330 707.



**BD Diagnostics** Women's Health and Cancer Tullastrasse 8-12 D-69126 Heidelberg Germany

For Europe, Middle East and Africa Phone: +32 53 720 211 Email: TriPathEurope@BD.com www.bd.com







A. Slides with scores below the primary threshold can be archived with no further review

B. Slides with scores the primary threshold are reviewed by cytotechnologists

C. Slides with scores are re-screened by cytotechnologists



Once the **BD FocalPoint<sup>™</sup> Slide Profiler** has screened all slides, the fields on the slides, most likely to contain abnormal cells, are presented to the cytotechnologist by the BD FocalPoint<sup>™</sup> GS workstation. The motorized stage of the microscope enables an easy and quick review of these fields on the slides.

(1) Optional Capability.



**BD Diagnostics** Women's Health and Cancer Tullastrasse 8-12 D-69126 Heidelberg Germany

For Europe, Middle East and Africa Phone: +32 53 720 211 Email: TriPathEurope@BD.com www.bd.com

Product availability has to be confirmed by your local representative.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2010 BD. XEUR5116-09. Becton Dickinson GmbH Tullastrasse 8-12, D-69126 Heidelberg. Sitz: Heidelberg. Geschäftsführer: Matthias Borst. Amtsgericht Mannheim HRB 330 707.





# Choose the multi-tasker

BD SurePath<sup>™</sup> Liquid-based Pap test One vial, multiple tests.

	0000000		
00	0000000000000		
000000	000000000000		
000000	00000000000		
000000	BD SurePath™ Liquid-based	Pan test is a versatile	•
<ul> <li>O</li> <li>O</li> </ul>	collection medium, fully co		•
<b>o</b> o o	of assays:	• • • • •	• •
•			• •
<b>o</b> •	• •		•
•	• Immunocytochemistry	• • • • • • • • •	• •
	The residual patient sample can a immunocytochemistry tests ( <b>BD S</b> Immunocytochemical Test).		
	Additional <b>BD SurePath</b> <sup>™</sup> slides of from the <b>BD SurePath</b> <sup>™</sup> enriched • A variety of molecular assays	d cell pellet.	
	Assay types	Disease examples	
	<ul> <li>Hybrid Capture<sup>®</sup></li> </ul>	<ul> <li>Human Papillomavirus</li> </ul>	
	• PCR	<ul> <li>Chlamydia Trachomatis</li> </ul>	
	• ISH	• Neisseria Gonorrhea	
	Genotyping	Herpes Simplex Virus	
	• NASBA	Trichomoniasis	
	Methylation-specific PCR		
	<ul> <li>Invader<sup>®</sup> Molecular Chemistry</li> <li>MicroArray</li> </ul>		
		For further information, please contact our Sales Representative.	



**BD Diagnostics** Women's Health and Cancer Tullastrasse 8-12 D-69126 Heidelberg Germany

For Europe, Middle East and Africa Phone: +32 53 720 211 Email: TriPathEurope@BD.com www.bd.com

Product availability has to be confirmed by your local representative. BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2010 BD. XEUR5117-09. Becton Dickinson GmbH Tullastrasse 8-12, D-69126 Heidelberg. Sitz: Heidelberg. Geschäftsführer: Matthias Borst. Amtsgericht Mannheim HRB 330 707.



## Reduce the risk of missed disease

The BD SurePath<sup>™</sup> Pap test with the power of the BD FocalPoint<sup>™</sup> GS Imaging System is one optimal combination to find cervical dysplasia. O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O

cervical dysplasia.

## • Because all collected cells are sent to the lab

Independent studies show that 2/3 of false negative Pap smears are the result of cells not being collected into the sampling vial or not being transferred to the slide <sup>(1)</sup>. On average, 37% of cellular material may be lost using the swirl and rinse technique <sup>(2)</sup>. The BD SurePath<sup>™</sup> collection ensures 100% of all collected cells go to the lab.

• Because diagnostically relevant cells are visible on the slide

Blood and obscuring materials can result in unsatisfactory slides with conventional and liquidbased Pap methods. Moreover, women with cancer have an increased likelihood of having blood in the cervical sample. The BD SurePath<sup>™</sup> cell enrichment process <sup>(3)</sup> separates and selectively removes obscuring debris providing optimal visualization of diagnostically relevant cells .

- Because diagnostically relevant cells **are brought to your attention** The BD FocalPoint<sup>™</sup> GS Imaging System <sup>(4)</sup> improves the quality of slide reading by:
- Directing your attention to slides most likely to contain abnormalities
- Guiding you to specific areas on the slide most likely to contain abnormal cells or information of diagnostic interest

## One combination for reliable cytological screening.

### **References:**

 Hutchinson M., Isenstein L., Goodman A., Hurley A., Douglass K., Mui K., Patten F., and Zahniser D Homogenous Sampling Accounts for the Increased Diagnostic Accuracy Using the ThinPrep<sup>™</sup> Processor. Am J Clin Pathol. 101:215-219, 1994.
 Bigras G., Rieder M., Lambercy J., Kunz B., Chatelain J., Reymond O., and Cornaz D. Keeping Collecting Device in Liquid Medium Is Mandatory to Ensure Optimized Liquid-Based Cervical Cytologic Sampling. J Low Genit Tract Dis. 7:168-174, 2003.

(3) Package insert BD PrepStain<sup>™</sup>.

(4) Package insert of BD FocalPoint<sup>™</sup> GS Imaging System.

Product availability has to be confirmed by your local representative.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2010 BD. XEUR5118-09. Becton Dickinson GmbH Tullastrasse 8-12, D-69126 Heidelberg. Sitz: Heidelberg. Geschäftsführer: Matthias Borst Amtsgericht Mannheim HRB 330 707.



**BD Diagnostics** Women's Health and Cancer Tullastrasse 8-12 D-69126 Heidelberg Germany

For Europe, Middle East and Africa Phone: +32 53 720 211 Email: TriPathEurope@BD.com www.bd.com